The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CATX | -13.54% | -40.21% | -9.77% | -72% |
| S&P | +14.77% | +87.2% | +13.35% | +469% |
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Richland, WA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $209.00K | -43.4% |
| Gross Profit | -$566.00K | -88.7% |
| Gross Margin | -270.81% | -189.5% |
| Market Cap | $254.72M | -71.7% |
| Market Cap / Employee | $1.82M | 0.0% |
| Employees | 140 | 0.0% |
| Net Income | -$25,969.00K | -71.7% |
| EBITDA | -$27,086.00K | -50.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.76M | -88.2% |
| Accounts Receivable | $179.00K | -17.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.55M | -22.9% |
| Short Term Debt | $759.00K | -20.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -30.98% | 0.0% |
| Return On Invested Capital | -37.46% | 10.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18,284.00K | 30.6% |
| Operating Free Cash Flow | -$16,292.00K | -584.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.66 | 0.52 | 0.89 | 0.96 | -63.68% |
| Price to Sales | 155.05 | 104.77 | 206.78 | 237.06 | - |
| Price to Tangible Book Value | 0.85 | 0.63 | 1.09 | 1.18 | -64.98% |
| Enterprise Value to EBITDA | -0.13 | 2.55 | -2.89 | -3.10 | -91.80% |
| Return on Equity | -32.9% | -31.5% | -37.2% | - | |
| Total Debt | $4.06M | $3.82M | $3.57M | $3.31M | -22.38% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
